Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Investing Activities (2016 - 2025)

Tg Therapeutics has reported Cash from Investing Activities over the past 10 years, most recently at -$15.6 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$15.6 million for Q4 2025, down 199.05% from a year ago — trailing twelve months through Dec 2025 was $13.8 million (up 1431.95% YoY), and the annual figure for FY2025 was $13.8 million, up 1431.95%.
  • Cash from Investing Activities for Q4 2025 was -$15.6 million at Tg Therapeutics, down from $46.4 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for TGTX hit a ceiling of $46.4 million in Q3 2025 and a floor of -$44.8 million in Q4 2023.
  • Median Cash from Investing Activities over the past 5 years was -$2.7 million (2021), compared with a mean of -$2.9 million.
  • Biggest five-year swings in Cash from Investing Activities: crashed 8396.3% in 2022 and later skyrocketed 596.71% in 2025.
  • Tg Therapeutics' Cash from Investing Activities stood at $3.3 million in 2021, then surged by 394.8% to $16.3 million in 2022, then tumbled by 375.09% to -$44.8 million in 2023, then surged by 135.28% to $15.8 million in 2024, then crashed by 199.05% to -$15.6 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$15.6 million (Q4 2025), $46.4 million (Q3 2025), and -$4.0 million (Q2 2025) per Business Quant data.